Like what has been measured above in plasma, Survivin was also detectable in the serum from patients having no prior diagnosis of cancer as well as in patients having the diagnosis of benign prostatic hyperplasia (BPH) and those diagnosed with prostate cancer (PCa) (Figure 1B). Here, BIRC5 is linked to benign prostatic hyperplasia.